Jevtana (Cabazitaxel)

Jevtana (cabazitaxel) is used within the taxane chemotherapy pathway for advanced prostate cancer.

• Metastatic castration‑resistant prostate cancer: improves overall survival in patients previously treated with docetaxel.
• Advanced prostate cancer after docetaxel failure: offers an alternative taxane option to control disease progression.
• Prostate adenocarcinoma with progression: reduces tumor burden when combined with standard corticosteroid support.

• Cabazitaxel binds to β‑tubulin subunits, promoting microtubule assembly and stabilizing the polymerized structure. This prevents depolymerization, disrupts mitotic spindle formation, arrests cells in the G2/M phase, and ultimately triggers apoptosis of rapidly dividing cancer cells.

Cabazitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count leading to infection risk.
• Fatigue: persistent tiredness affecting daily activities.
• Anemia: reduced red blood cell levels causing weakness.
• Nausea: upset stomach often accompanied by vomiting.
• Diarrhea: loose stools that may require supportive care.
• Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent treatment.
• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Peripheral neuropathy: nerve damage causing tingling or pain.
• Life‑threatening infections: sepsis or pneumonia.
• Pulmonary toxicity: interstitial lung disease or pneumonitis.
• Cardiac events: arrhythmias or myocardial ischemia.

Prior to initiating cabazitaxel therapy, clinicians should assess patient suitability and monitor for potential complications.

• Monitor blood counts: perform regular CBC to detect neutropenia and anemia.
• Assess hepatic function: adjust dosing in patients with liver impairment.
• Evaluate for hypersensitivity: observe for infusion‑related reactions during administration.
• Use caution in elderly: increased risk of myelosuppression and infection.
• Avoid in active severe infection: postpone treatment until infection resolves.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Concurrent myelosuppressive agents: heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely)

• CYP2C8 inhibitors (e.g., gemfibrozil): may modestly raise plasma levels.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk.
• Neurotoxic drugs (e.g., vincristine): observe for additive peripheral neuropathy.